Litvack Frank 4

What Happened

• Frank Litvack, a director of Capricor Therapeutics (CAPR), exercised stock options on May 13, 2026 to acquire 3,937 common shares at an exercise price of $1.39 per share, for a total cash payment of $5,472. The filing shows the derivative position (the option) was converted/removed as part of the exercise.

Key Details

• Transaction date: May 13, 2026; Form 4 filed May 14, 2026 (appears timely).
• Transaction code: M (option exercise/conversion).
• Shares acquired: 3,937 shares at $1.39 each; total cost $5,472.
• Derivative removed: 3,937-option-equivalent reported disposed (represents conversion of the option into stock).
• Post-transaction holdings: total shares owned after the transaction are not specified in this Form 4.
• Footnotes: shares are held by the Litvack Curtis Family Trust (Frank Litvack is trustee). The option was originally granted June 2, 2016, adjusted for a 1-for-10 reverse split (June 4, 2019) and a repricing to $1.39 on Feb 12, 2020; vesting occurred in 2016 per the grant notes.

Context

• This was an exercise of previously granted options (not an immediate sale). The filing shows acquisition of shares by paying the exercise price rather than a cashless/sale-exercise, so Litvack retained the shares rather than selling them immediately.
• Option exercises often reflect routine option maturities/vesting and do not by themselves indicate a view on the company's near-term prospects.